The University of Texas MD Anderson Cancer Center today named Welela Tereffe, M.D., as chief medical executive (CME). Recognized as a patient-centered and institutionally minded leader, Tereffe assumes this new position and joins the institution’s Executive Leadership Team (ELT) on Jan. 1, 2021. In the role of CME, Tereffe will engage physicians and advanced practice providers in the delivery of outstanding research-driven clinical care that includes the Texas Medical Center campus, community and academic settings in […]
University of Texas MD Anderson Cancer Center
Md Anderson And Obsidian Therapeutics Announce Strategic Collaboration To Accelerate Advancement Of Novel Engineered Tumor Infiltrating Lymphocyte Therapy (Cytotil) For Solid Tumors
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced a multi-year strategic collaboration designed to expedite the research and development of novel engineered tumor infiltrating lymphocytes (TILs) for the treatment of solid tumors. The agreement pairs Obsidian and its novel cytoDRiVE™ technology platform with MD Anderson’s extensive experience and state-of-the-art capabilities in TIL cell therapy, led by the Biologics Development platform, within the Therapeutics Discovery division. The collaboration is focused on developing TIL armored with regulated […]
Study identifies characteristics of infused CAR T cells associated with efficacy and toxicity in patients with large B-cell lymphoma
Findings suggest that monitoring early changes in circulating tumor DNA may predict patient outcomes Researchers at The University of Texas MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19 CAR T cell infusion products associated with how patients with large B-cell lymphoma (LBCL) respond to treatment and develop side effects. The research team also found that early changes in circulating tumor DNA one week after CAR T cell therapy may be predictive of treatment response in a particular patient. The paper was published online […]
Genetically enhanced, cord-blood derived immune cells strike B-cell cancers
HOUSTON – Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down cells with specific targets on them to treat cancer, researchers at The University of Texas MD Anderson Cancer Center report in the journal Leukemia. The team’s preclinical research shows that natural killer cells derived from donated umbilical cords can be modified to seek and destroy some types of leukemia and […]